{'fraction_non_alphanumeric': 0.03341013824884793, 'fraction_numerical': 0.020737327188940093, 'mean_word_length': 5.533834586466165, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Continuous infusion 5‐fluorouracil plus weekly cisplatin for pancreatic carcinoma. A mid‐atlantic oncology program study

Fifty‐six previously untreated patients with biopsy‐proven, locally advanced or metastatic and measurable adenocarcinoma of the pancreas were treated with the combination of a protracted intravenous infusion of 5‐fluorouracil (5‐FU) and low dose weekly bolus cisplatin administered continuously for 10 weeks followed by a 2‐week rest period. The objective response rate was 16% with two patients (4%) achieving a complete response (confidence intervals, 8% to 29%). The median survival time for all treated patients was 5.8 months; however, 26% of all patients were alive at 1 year. Both median survival time and the proportion alive at 1 year exceed that of prior reports involving large patient groups, possibly due to better patient selection.